NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/31/2022
Back to search
Official data from USPTO
YIPSCELL
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
41
Latest update
05/31/2022
Trademark type
Word
Nice classes
5, 42
Filing date
10/09/2020
Registration date
05/31/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/31/2022
Last transaction
05/31/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
12/31/2021
First use in commerce
12/31/2021
Drawing code
4
Owner type
03
Owner location
Seoul, KR
Examiner
HUTCHISON, DAVID
Law office
N50
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
CiSTEM Inc.
Representatives
minchul yang STIP LAW GROUP LLC
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
pharmaceutical preparations for the treatment of musculo-skeletal disordersdamaged skin and tissuefor treating and preventing tendon and muscle injuries and disorderssports related injuriesfor treating and preventing knee cartilage and meniscus injuries and disordersfor knee cartilage and meniscus regeneration; medicinal preparations for musculo-skeletal disordersdamaged skin and tissuefor treating and preventing tendon and muscle injuries and disorderssports related injuriesfor treating and preventing knee cartilage and meniscus injuries and disordersfor knee cartilage and meniscus regeneration; biochemical preparations for medical purposesfor the diagnosis and treatment of musculo-skeletal disordersdamaged skin and tissuefor treating and preventing tendon and muscle injuries and disorderssports related injuriesfor treating and preventing knee cartilage and meniscus injuries and disordersfor knee cartilage and meniscus regeneration; pharmaceutical preparations for the treatment of viral and infectious diseasesautoimmune diseaseskidney diseaseshepatic diseasesneurological diseases and bone diseases; stem cells for medical and veterinary purposes; cultured cells comprised of stem cells for medical useinjection and impanation for treatment of cartilage and meniscus injuries; cells for medical use; cellular function activating agents for medical purposes; cell growth media for growing cells for medical use; reagent kits for medical purposes comprising chemical agentsskincartilage and other cells; culture media for cultivating human cells for use in augmentation of bone and other tissues for medical purpose using induced pluripotent cells and embryonic stem-like cells and other stem cells; kit containing chemical media additives being cell growth media for growing cells for medical and veterinary purposes; culture media for cultivating human cells for use in regenerative medicineoncologyhepatology and hematology; chemicalbiochemicalbiologicalcell biological products for medical purposesinduced pluripotent stem cells (iPSCs)cell mediacell culture supplements and reagents for cell suspensioncell growth and cell storage; medicinespharmaceutical products and preparations for health careinduced pluripotent stem cells (iPSCs) and iPSC cultures; cell cultures and cell culture systems for human cells and for medical purposesinduced pluripotent stem cells (iPSCs) and freeze-conserved cellsreagents for sub cultivation of the cells; intestinal epithelial cell preparations for the treatment of gastrointestinal diseases; pharmaceutical preparations to evaluate the toxicitymetabolismdrug absorption and compound efficacy of the small intestines; medicinal preparations to evaluate the toxicitymetabolismdrug absorption and compound efficacy of the small intestines; intestinal epithelial cells for medical purposes; pharmaceutical preparationslive cells in the nature of smooth muscle cellsskeletal muscle cellsmyocytesfibroblastschondrocytesadipocytesfibromyoblastsectodermal cellshepatocytesorgan cellsliver cellskidney cellscardiac cellspancreatic islet cellscells present in the intestinestem cellsosteoblastscells forming bone or cartilagehematopoietic cellsparenchymal cellsstroma cellstotipotent cells (iTC)pluripotent cells (iPSC)progenitor cells (iMSC) for medical purposes; biological implantslive tissue intended for subsequent implantation; pharmaceutical preparations and drug delivery systems comprising chemical agents and stem cells for the treatment of osteoarthritiscartilage defectscartilage injury; cellsepithelial cellsorganoids and cell cultures for personalised medicinefor diagnosis and treatment of diseases or disorders of epithelial tissue in the sensoryreproductiveurinarydigestivecirculatoryendocrinenervouslymphaticintegumentaryrespiratory systems; modified stem cells suitable for use as pharmaceutical biologicals used to regenerate neural and spinal cord tissues in humans
Class 42
stem cell research services; research and development services in the field of cytology; custom cell culturing services for scientific and research purposes; testinginspectionresearch and development of cell and tissue culturing; research and development of medicines; scientific investigations for medical purposes; custom design and development of chemical reagents scientific services relating to the isolation and cultivation of human tissues and cells for research purposes; research and development and consultation related thereto in the field of antibodiesantibody technologychemistryagrochemical pharmaceuticalsbioinformaticsbiomedical devicesbiologicsbiotechnologybiotherapeuticsbiologybiochemical preparationscell lineschemoinformaticgenetics and genetic engineeringgene expression systemsin vitro researchinhalation pharmaceuticalsmolecular sciencesmicro-organismsnutritionophthalmic preparationspharmacogeneticspharmacokineticspharmacologypharmaceuticalspolymerspeptide synthesisproteinsolid state characterization; scientific and technological servicesscientific researchdevelopmentanalysistestingtechnological servicesscientific researchdevelopmentanalysistestingengineeringextractionsynthesispurification and production in the field of antibodiesactive pharmaceutical ingredients (API)biomoleculescell bank characterizationchiralitychromosome aberrationclinical chemistrycloning vectorcyclotidesDNAflow cytometrygas chromatography mass spectrometrygeneimmuno-pharmaceuticalsin vitro irritationlarge moleculeliquid chromatography mass spectrometrymicrobialmonomernanoparticlenatural productspeptidesproteinsRNAsupercritical fluid chromatographysmall molecules and vaccines; biotechnology research; medical research and development in the field of tissue and cell fabrication; biologic services in the nature of biologic research; biomedical serviceslaboratory services for human tissuebloodblood components and stem cells for medical use; medical and scientific laboratory servicesdevelopment of induced pluripotent stem cells using cells derived from healthy and ill humans; medical and scientific laboratory servicesdevelopment of induced pluripotent stem cell lines using customized primary cells; medical and scientific laboratory servicesevaluating of drugs capable of differentiating various serovars suitable for diseases using induced pluripotent stem cells; medical and scientific laboratory servicesevaluating of drug efficacy for technology for making animal models of various diseases; medical and scientific laboratory servicesevaluating of the quality of induced pluripotent stem cells; medical servicesresearch services relating to stem cells; researchdevelopment and testing services for others in the fields of genomicsbiotechnologychemistry and pharmaceuticals; conducting clinical trials for others in the field of stem cell based therapies and products; scientific research servicestrackinganalyzingforecastingreporting data in the field of clinical trials of stem cell based therapies and products
Publications
History of USPTO decisions and trademark events.
41 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
05/31/2022
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
04/23/2022
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
04/22/2022
SUPC
STATEMENT OF USE PROCESSING COMPLETE
04/22/2022
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
04/22/2022
IUAF
USE AMENDMENT FILED
04/11/2022
EISU
TEAS STATEMENT OF USE RECEIVED
04/11/2022
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
02/08/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/14/2021
PUBO
PUBLISHED FOR OPPOSITION
12/14/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/24/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/09/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
11/08/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/08/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
11/08/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/08/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/05/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/04/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/04/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/23/2021
GNRT
NON-FINAL ACTION E-MAILED
10/23/2021
CNRT
NON-FINAL ACTION WRITTEN
10/23/2021
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
10/19/2021
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
10/12/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/27/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/24/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/24/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/24/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/04/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/04/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/04/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/28/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/28/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/28/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/01/2021
GNRT
NON-FINAL ACTION E-MAILED
04/01/2021
CNRT
NON-FINAL ACTION WRITTEN
04/01/2021
DOCK
ASSIGNED TO EXAMINER
03/09/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/24/2020
NWAP
NEW APPLICATION ENTERED
10/13/2020
Continuous trademark protection
Get notified about every new filing that threatens YIPSCELL or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.